The company manufactures solar photovoltaic modules and provides related job-work services, operating as a subsidiary of Waaree Energies to serve the renewable energy market.
The company lacks a durable moat as it operates in a highly commoditized industry with returns heavily dependent on parent-company support and government protectionist policies like ALMM. While ROCE appears high in the quant snapshot, this is distorted by a tiny capital base following insolvency restructuring rather than genuine pricing power or cost advantages.
Capital allocation has been dominated by the 2022 insolvency resolution process where Waaree Energies took control. Recent activity focuses on restarting production and upgrading lines to TOPCon technology, funded largely through parent-company loans and related-party sales.
The company collapsed after its parent, Waaree Energies, pivoted its strategic focus, leaving Indosolar as a hollow shell with no independent customer base. The artificial financial metrics, once inflated by a decimated capital base post-insolvency, reverted to the mean as the company failed to achieve scale in the commoditized TOPCon market. Without the crutch of related-party loans and captive sales, the lack of genuine pricing power led to a liquidity crunch, and the inability to meet public shareholding norms eventually resulted in regulatory delisting or a forced fire sale.
RichFakir rates Indosolar Ltd's business quality as decent — 56/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Indosolar Ltd is trading about 27% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Indosolar Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Indosolar Ltd's fair value is about ₹262 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →